
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Jerry Fahrni discusses his blog post about how integration is no longer optional for pharmacy technology.
Jerry Fahrni discusses his blog post about how integration is no longer optional for pharmacy technology.






